Baird lowered the firm’s price target on Owens & Minor to $18 from $21 and keeps a Neutral rating on the shares. The firm noted the Street is cautious over medical volumes, GLP-1 impacts in both segments particularly Patient Direct, PPE destocking, leverage, and more.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on OMI: